Breast Cancer Just Got 3 New Drugs — Here's What Changed
If you have estrogen receptor positive, HER2 negative breast cancer, the standard of care was just rewritten. The drug oncologists have reached for in hormone receptor positive breast cancer for nearly 25 years just got outperformed — not once, but three times, by three new drugs: vepdegestrant, camizestrant, and giredestrant. Each is a SERD, each works differently, and each belongs at a different point in your treatment journey. Understanding ESR1 mutations, aromatase inhibitor resistance, liquid biopsy testing, and targeted therapy options has never been more directly relevant to your treatment decisions.
Why Your Current Treatment May Already Be Losing the Fight
When you block estrogen with an aromatase inhibitor, most tumor cells stop growing. But any rare cells with a mutation that lets the estrogen receptor activate itself without estrogen will survive, multiply, and eventually take over. This is an ESR1 activating mutation. It develops in approximately 40 to 50 percent of patients on aromatase inhibitors plus CDK4/6 inhibitors. Once dominant, blocking estrogen is completely irrelevant — you get all the side effects with none of the benefit. This is not bad luck. It is evolution.
Fulvestrant: Why the Old SERD Standard Is Now the Weak Comparator
Fulvestrant has been the only approved SERD for almost 25 years. It binds to the estrogen receptor and makes it less stable, but relies on the cell's own cleanup machinery — an inefficient process. At maximum dose it achieves only 50 to 80 percent receptor suppression. In ESR1 mutant disease it produces a median progression free survival of just 2.1 months. Every new drug in this video was tested against fulvestrant. Every single one beat it.
Vepdegestrant: A New Mechanism That's Already Available Now
Vepdegestrant works through a completely new cancer drug mechanism called a PROTAC. It actively recruits the cell's disposal machinery, tags the estrogen receptor directly, and sends it to be destroyed — then releases itself to find another receptor and do it again. The VERITAC-2 trial showed a 43 percent reduction in risk of progression or death in ESR1 mutant disease and nearly five times the tumor response rate of fulvestrant. It is an oral daily pill and it is FDA approved right now.
Camizestrant and Giredestrant: Interception Before Damage
Camizestrant targets patients whose liquid biopsy detects an ESR1 mutation before clinical progression — a proactive switch that cut progression risk by 56 percent in the SERENA-6 trial. Giredestrant goes even further, showing a 30 percent reduction in recurrence risk in early stage breast cancer patients in the LIDERA trial — beating tamoxifen and aromatase inhibitors in adjuvant treatment for the first time in 25 years. Neither is FDA approved yet, but giredestrant has a decision date by December 2026.
The One Question to Ask at Your Next Appointment
Have you been tested for ESR1 mutations? If you have been on an aromatase inhibitor, the probability of having developed this mutation is up to 50 percent. Ask your oncologist specifically.
Accurate science saves lives — and it starts with rejecting simple myths in favor of real understanding. Stay curious.
Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.